Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
Takebe N, Coyne GO, Kummar S, Collins J, Reid JM, Piekarz R, Moore N, Juwara L, Johnson BC, Bishop R, Lin FI, Mena E, Choyke PL, Lindenberg ML, Rubinstein LV, Bonilla CM, Goetz MP, Ames MM, McGovern RM, Streicher H, Covey JM, Doroshow JH, Chen AP. Takebe N, et al. Among authors: kummar s. Oncotarget. 2021 Feb 16;12(4):268-277. doi: 10.18632/oncotarget.27887. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659039 Free PMC article.
Compressing drug development timelines in oncology using phase '0' trials.
Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Kummar S, et al. Nat Rev Cancer. 2007 Feb;7(2):131-9. doi: 10.1038/nrc2066. Nat Rev Cancer. 2007. PMID: 17251919 Review.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ. Kummar S, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7. doi: 10.1158/1078-0432.CCR-07-0791. Clin Cancer Res. 2007. PMID: 17875771 Clinical Trial.
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH. Kinders R, et al. Among authors: kummar s. Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Mol Interv. 2007. PMID: 18199854 Review.
Phase 0 clinical trials: conceptions and misconceptions.
Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH. Kummar S, et al. Cancer J. 2008 May-Jun;14(3):133-7. doi: 10.1097/PPO.0b013e318172d6f3. Cancer J. 2008. PMID: 18536551 Free PMC article. Review.
Designing phase 0 cancer clinical trials.
Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Murgo AJ, et al. Among authors: kummar s. Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560. Clin Cancer Res. 2008. PMID: 18559582 Free PMC article.
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Kummar S, et al. J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364967 Free PMC article. Clinical Trial.
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH; National Cancer Institute Phase 0 Working Group. Yang SX, et al. Among authors: kummar s. Cancer Biol Ther. 2009 Nov;8(21):2004-9. doi: 10.4161/cbt.8.21.9917. Epub 2009 Nov 25. Cancer Biol Ther. 2009. PMID: 19823047 Free article.
177 results